Once-Weekly Semaglutide in Adults With Overweight or Obesity (March 2021) Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (July 01, 2024) Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes (December 18, 2018) Dietary Protein, Weight Loss, and Weight Maintenance (April 28, 2009) Brief communication: Sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite (December 12, 2004) Enhanced Cortisol Production Rates, Free Cortisol, and 11BETA-Hsd-1 Expression Correlate With Visceral Fat and Insulin Resistance in Men: Effect of Weight Loss (February 2009) Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (February 21, 2024)

No dosage adjustment is needed for paracetamol when taken with Semaglutide
Rybelsus comes in 3mg, 7mg, and 14mg tablets and is generally taken once daily, often under the supervision of a doctor or consultant
There are no specific increased risks, though gastrointestinal side effects from the medication may overlap with postcholecystectomy digestive changes